InsidersTradesSigma
Total declarations
Companies
▲ Purchases (0 ops.)
▼ Sales (1 ops.)
Insider track record
Board DirectorDisclosed buys
0
Disclosed sells
1
T+90 hit rate
0%
T+90 mean return
-10.2%
Across 6 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Explore the detailed record of transactions filed by Lee Howard, Director. Officer active across 2 companies, notably Amphastar Pharmaceuticals, Inc.. Aggregated, 16 filings have been published. Breakdown: 0 buy · 1 sell. Total volume traded: €364k. Activity tracked since 20 May 2021. The latest transaction was filed on 1 June 2026 (Attribution). Regulator: SEC (Form 4). All data is accessible without signup.
Declarations16 total
8,143 shares0Common StockSEC:0001379941-26-000003:0
769 shares@ US$18.450.0010% mcap1.9% of flowCommon StockSEC:0001379941-26-000003:1
3,076 shares0Common StockSEC:0001415889-24-015689:0
375 shares@ US$45.672.4% of flowCommon StockSEC:0001104659-23-070331:0
2,716 shares0Common StockSEC:0001104659-23-068975:0
16,679 shares@ US$16.6939.8% of flowCommon StockSEC:0001104659-23-068054:0
4,163 shares0Common StockSEC:0001104659-22-071077:0
10,291 shares@ US$17.110.013% mcap20.3% of flowCommon StockSEC:0001104659-22-069072:0
10,291 shares@ US$37.786355.9% of flowCommon StockSEC:0001104659-22-069072:1
10,000 shares@ US$17.110.013% mcap19.8% of flowCommon StockSEC:0001104659-22-064834:0
157 shares@ US$19.920.3% of flowCommon StockSEC:0001104659-21-080763
157 shares@ US$19.920.0002% mcap0.3% of flowCommon StockSEC:0001104659-21-080763:0
7,827 shares@ US$16.4313.0% of flowCommon StockSEC:0001104659-21-078411
7,827 shares@ US$16.430.0086% mcap13.0% of flowCommon StockSEC:0001104659-21-078411:0
10,000 shares@ US$16.4316.6% of flowCommon StockSEC:0001104659-21-071269
10,000 shares@ US$16.430.011% mcap16.6% of flowCommon StockSEC:0001104659-21-071269:0
16 of 16 declarations
About Lee Howard
Howard Lee is a Board Member at Amphastar Pharmaceuticals, Inc. He contributes to the governance of the company and strategy formulation. His experience in the pharmaceutical sector allows him to provide valuable insights into market challenges and opportunities.
